GBA's "2021 Stock Phantasma"

janes said:
Ok, i took some time tonight to look into upcoming catalysts for IOVA and XAIR and typing them up here so I can keep them straight:

IOVA. i looked into this on june 6, and at that time it seemed the melonoma (followed by cervical cancer) BLA's were shifted to the first half of 2022. a smaller event would be the release of the full cohort 4 data of the melanoma which they have held back as they deal with the FDA. Second quarter financial results conference call scheduled for Thursday, August 5, and maybe we can get revised dates then. Chardin has them as a buy with target of $51.

XAIR. i never found a transcript for last week's investor presentation. people online seem to expect to hear from FDA august or september. in the xair quarterly report from 6/30, they said "we anticipate an FDA response towards the end of calendar 3Q 2021." Turns out this would have been a good buy this morning; it fell down to $6.06 at opening, and then recovered 9% to 6.60 by EOD.
More...

Research from July
 
stonedinvestor said:
Porch is one of these good SPAC's... There are not too many... MTTR Mattaport... The bio plastic guys DNMR and PORCH... These have been the best.

I watched PRCH go from $11-->$20 without buying it came way back but impressive as heck that they are back up around $20 as a former SPAC... Very slowly we are seeing a precious few float to the top.

Will Wheels Up or Blade follow?
More...
 
LETS GET A WATCH LIST TOGETHER!

ZI)


This company is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +8.3%.

Revenues are expected to be $207.42 million, up 48.5% from the year-ago quarter

I THINK THEY CAN BEAT THAT 13 CENTS NUMBER BUT WHAT OF FORWARD GUIDE????
 
You must log in or register to reply here.
Back
Top